Cargando…

Gender differences in hereditary hemorrhagic telangiectasia severity

BACKGROUND: Gender differences in organ involvement and clinical severity have been poorly described in hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to describe differences in the severity of HHT manifestations according to gender. METHODS: Severity was measured according t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora-Luján, J. M., Iriarte, A., Alba, E., Sánchez-Corral, M. A., Cerdà, P., Cruellas, F., Ordi, Q., Corbella, X., Ribas, J., Castellote, J., Riera-Mestre, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053104/
https://www.ncbi.nlm.nih.gov/pubmed/32122373
http://dx.doi.org/10.1186/s13023-020-1337-5
_version_ 1783502974567317504
author Mora-Luján, J. M.
Iriarte, A.
Alba, E.
Sánchez-Corral, M. A.
Cerdà, P.
Cruellas, F.
Ordi, Q.
Corbella, X.
Ribas, J.
Castellote, J.
Riera-Mestre, A.
author_facet Mora-Luján, J. M.
Iriarte, A.
Alba, E.
Sánchez-Corral, M. A.
Cerdà, P.
Cruellas, F.
Ordi, Q.
Corbella, X.
Ribas, J.
Castellote, J.
Riera-Mestre, A.
author_sort Mora-Luján, J. M.
collection PubMed
description BACKGROUND: Gender differences in organ involvement and clinical severity have been poorly described in hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to describe differences in the severity of HHT manifestations according to gender. METHODS: Severity was measured according to Epistaxis Severity Score (ESS), Simple Clinical Scoring Index for hepatic involvement, a general HHT-score, needing for invasive treatment (pulmonary or brain arteriovenous malformations -AVMs- embolization, liver transplantation or Young’s surgery) or the presence of adverse outcomes (severe anemia, emergency department -ED- or hospital admissions and mortality). RESULTS: One hundred forty-two (58.7%) women and 100 (41.3%) men were included with a mean age of 48.9 ± 16.6 and 49 ± 16.5 years, respectively. Women presented hepatic manifestations (7.1% vs 0%) and hepatic involvement (59.8% vs 47%), hepatic AVMs (28.2% vs 13%) and bile duct dilatation (4.9% vs 0%) at abdominal CT, and pulmonary AVMs at thoracic CT (35.2% vs 23%) more often than men. The Simple Clinical Scoring Index was higher in women (3.38 ± 1.2 vs 2.03 ± 1.2), and more men were considered at low risk of harboring clinically significant liver disease than women (61% vs 25.3%). These differences were mantained when considering HHT1 and HHT2 patients separetely. Duodenal telangiectasia were more frequent in men than women (21% vs 9.8%). Invasive treatments were more frequently needed in women (28.2% vs 16%) but men needed attention at the ED more often than women (48% vs 28.2%), with no differences in ESS, HHT-score, anemia hospital admissions or mortality. CONCLUSIONS: HHT women showed more severe hepatic involvement than men, also among HHT1 and HHT2 patients. Women had higher prevalence of pulmonary AVMs and needed invasive procedures more frequently, while men needed attention at the ED more often. These data might help physicians to individualize HHT patients follow-up.
format Online
Article
Text
id pubmed-7053104
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70531042020-03-10 Gender differences in hereditary hemorrhagic telangiectasia severity Mora-Luján, J. M. Iriarte, A. Alba, E. Sánchez-Corral, M. A. Cerdà, P. Cruellas, F. Ordi, Q. Corbella, X. Ribas, J. Castellote, J. Riera-Mestre, A. Orphanet J Rare Dis Research BACKGROUND: Gender differences in organ involvement and clinical severity have been poorly described in hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to describe differences in the severity of HHT manifestations according to gender. METHODS: Severity was measured according to Epistaxis Severity Score (ESS), Simple Clinical Scoring Index for hepatic involvement, a general HHT-score, needing for invasive treatment (pulmonary or brain arteriovenous malformations -AVMs- embolization, liver transplantation or Young’s surgery) or the presence of adverse outcomes (severe anemia, emergency department -ED- or hospital admissions and mortality). RESULTS: One hundred forty-two (58.7%) women and 100 (41.3%) men were included with a mean age of 48.9 ± 16.6 and 49 ± 16.5 years, respectively. Women presented hepatic manifestations (7.1% vs 0%) and hepatic involvement (59.8% vs 47%), hepatic AVMs (28.2% vs 13%) and bile duct dilatation (4.9% vs 0%) at abdominal CT, and pulmonary AVMs at thoracic CT (35.2% vs 23%) more often than men. The Simple Clinical Scoring Index was higher in women (3.38 ± 1.2 vs 2.03 ± 1.2), and more men were considered at low risk of harboring clinically significant liver disease than women (61% vs 25.3%). These differences were mantained when considering HHT1 and HHT2 patients separetely. Duodenal telangiectasia were more frequent in men than women (21% vs 9.8%). Invasive treatments were more frequently needed in women (28.2% vs 16%) but men needed attention at the ED more often than women (48% vs 28.2%), with no differences in ESS, HHT-score, anemia hospital admissions or mortality. CONCLUSIONS: HHT women showed more severe hepatic involvement than men, also among HHT1 and HHT2 patients. Women had higher prevalence of pulmonary AVMs and needed invasive procedures more frequently, while men needed attention at the ED more often. These data might help physicians to individualize HHT patients follow-up. BioMed Central 2020-03-02 /pmc/articles/PMC7053104/ /pubmed/32122373 http://dx.doi.org/10.1186/s13023-020-1337-5 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mora-Luján, J. M.
Iriarte, A.
Alba, E.
Sánchez-Corral, M. A.
Cerdà, P.
Cruellas, F.
Ordi, Q.
Corbella, X.
Ribas, J.
Castellote, J.
Riera-Mestre, A.
Gender differences in hereditary hemorrhagic telangiectasia severity
title Gender differences in hereditary hemorrhagic telangiectasia severity
title_full Gender differences in hereditary hemorrhagic telangiectasia severity
title_fullStr Gender differences in hereditary hemorrhagic telangiectasia severity
title_full_unstemmed Gender differences in hereditary hemorrhagic telangiectasia severity
title_short Gender differences in hereditary hemorrhagic telangiectasia severity
title_sort gender differences in hereditary hemorrhagic telangiectasia severity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053104/
https://www.ncbi.nlm.nih.gov/pubmed/32122373
http://dx.doi.org/10.1186/s13023-020-1337-5
work_keys_str_mv AT moralujanjm genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT iriartea genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT albae genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT sanchezcorralma genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT cerdap genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT cruellasf genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT ordiq genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT corbellax genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT ribasj genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT castellotej genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity
AT rieramestrea genderdifferencesinhereditaryhemorrhagictelangiectasiaseverity